Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Pfizer Names Bush Cabinet Veteran Principi To Head Government Affairs

  • News

Executive Summary

Former Veterans Affairs Secretary Anthony Principi will replace Pfizer VP-Government Relations Kenneth Bowler as head of the company's government affairs staff effective March 15

You may also be interested in...



Pfizer Resumes Search For Government Affairs VP After Principi Resigns

Pfizer is resuming its search for a VP of government affairs to head the company's Washington, D.C. office following Anthony Principi's resignation

Pfizer Resumes Search For Government Affairs VP After Principi Resigns

Pfizer is resuming its search for a VP of government affairs to head the company's Washington, D.C. office following Anthony Principi's resignation

BioShield II May Revive Big Pharma’s Interest In Biodefense

The proposed "BioShield II" legislation is reviving big pharma's interest in the biodefense industry, McKenna Long & Aldridge Partner Frank Rapoport maintained March 3 at Equity International's Homeland & Global Security Summit in Washington, D.C

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS045513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By